Page 32 - Pfizer

Pfizer's Covid vaccine candidate prevents 90% of infections in large study

The findings are based on an interim analysis conducted after 94 participants contracted Covid-19

Pfizer says no Covid vaccine data yet, unlikely to come before US elections

An independent panel will conduct the first analysis when it reaches 32 infections.

UK starts real-time review of Moderna's Covid-19 vaccine candidate

Moderna said earlier this month it was going to apply for real-time reviews of its experimental Covid-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc and AstraZeneca

Drugmaker Pfizer not yet ready to release Covid-19 vaccine data

Pfizer said in a presentation that the independent monitor which will determine whether or not the trial has been successful has not conducted any interim efficacy analyses yet

Pfizer says earliest US filing for Covid-19 vaccine would be late November

People around the world are counting on a vaccine to control the spread of the coronavirus, which has killed more than a million people and ravaged the global economy

Pfizer confirms possible November coronavirus vaccine application

Safety review dictates the timeline, with the Food and Drug Administration requiring that at least half the people in the study be watched for side effects for two months

Pfizer could apply for emergency use of Covid-19 vaccine by late Nov

It would be the first time that Pfizer or any other leading Western vaccine developer provided such a specific timeline.

New Zealand signs deal with Pfizer, BioNTech for coronavirus vaccine

SYDNEY (Reuters) - The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany's BioNTech <22UAy.F>, with delivery potentially as early as the first quarter of 2021.

EU health regulator reviewing Pfizer-BioNTech Covid-19 vaccine in real time

The announcement by the European Medicines Agency (EMA) could speed up the process of approving a successful vaccine in the bloc

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

Pfizer's German development partner BioNTech on Thursday joined other leading Covid-19 vaccine developers in ruling out participation in British plans to test experimental inoculations

Johnson & Johnson kicks off giant study of single shot Covid-19 vaccine

J&J became the fourth vaccine maker to move its candidate into late-stage human studies in the US

Trump suggests Pfizer could win first US approval for Covid-19 vaccine

'Pfizer's doing really well', Trump said in an interview

Trump suggests Pfizer could win Covid vaccine approval, J&J to come later

WASHINGTON (Reuters) - U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.

Moderna and Pfizer reveal secret blueprints for virus vaccine trials

The companies, Moderna and Pfizer, revealed details about how participants are being selected and monitored

Pfizer vaccine trial bets on early win against coronavirus, documents show

Pfizer's clinical trial protocol outlines for the company, scientists and regulators how the drugmaker could show that its vaccine meets efficacy and safety standards set by USFDA

Pfizer, BioNTech to expand phase three trial for coronavirus vaccine

The US Food and Drug Administration (FDA) will have to approve the change in the Phase 3 Covid-19 vaccine trial before it goes into effect

US, European Covid-19 vaccine developers pledge to uphold testing rigour

The promise to play by established rules underlines a highly politicised debate over what action is needed to rein in Covid-19 quickly and to jumpstart global business and trade

BioNTech, Pfizer begin German part of coronavirus vaccine study

Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its Covid-19 vaccine candidate to include testing in its home country of Germany

Pfizer, BioNTech Covid-19 vaccine on track for regulatory review in October

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants

Covid-19 vaccine makers must deliver to US in time to get full payments

The Cambridge, Massachusetts, biotech's $1.5-billion deal pays out in full if its vaccine receives regulatory clearance by January 31, 2021